Evolus Q2 revenue $69.4M (+4% YoY); cuts FY2025 guidance to $295-305M; CEO appointed PFO, CMO departing

Evolus, Inc.

2025-Q2 EPS reported -$0.56 revenue$137,909,000

Q2 net revenue $69.4M, up 4% YoY; GAAP op loss $10.2M vs $7.7M loss YoY; non-GAAP op loss $7.9M vs $1.1M income.
FY2025 revenue guidance reset to $295-305M (11-15% growth); non-GAAP op expenses $208-213M with $25M savings.
Evolysse filler delivered $9.7M revenue in Q2, strongest filler launch quarter in over a decade.
CEO David Moatazedi appointed as Principal Financial Officer; CMO Tomoko Yamagishi-Dressler departing Aug 22, no disagreement.
Expects meaningful profitability in Q4 2025 and annual profitability from 2026; 15% Evolysse tariff minimal impact.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.